All In Biotech

Drug Trial Radar · NCT06926673

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

Dec 23, 2021

Primary completion

May 2, 2024

Study completion May 2, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.

Conditions

  • Neoplasms

Interventions

  • DostarlimabDrug

    Dostarlimab will be administered

  • Belrestotug.Drug

    Belrestotug will be administered

  • NelistotugDrug

    Nelistotug will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)Time frame: Up to approximately 97 weeks
  2. Part 1: Number of Participants With Any TEAEs and SAEs (Arm 5)Time frame: Up to approximately 107 weeks
  3. Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)Time frame: Up to 21 days
  4. Part 1: Number of Participants Requiring Dose Modifications (Arm 4)Time frame: Up to approximately 97 weeks
  5. Part 1: Number of Participants Requiring Dose Modifications (Arm 5)Time frame: Up to approximately 107 weeks
  6. Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)Time frame: Up to approximately 97 weeks
  7. Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)Time frame: Up to approximately 107 weeks
  8. Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)Time frame: Up to approximately 97 weeks
  9. Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)Time frame: Up to approximately 107 weeks
  10. Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)Time frame: Up to approximately 97 weeks
  11. Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)Time frame: Up to approximately 107 weeks
  12. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)Time frame: Up to approximately 97 weeks
  13. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)Time frame: Up to approximately 107 weeks
  14. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)Time frame: Up to approximately 97 weeks
  15. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)Time frame: Up to approximately 107 weeks
  16. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)Time frame: Up to approximately 97 weeks
  17. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)Time frame: Up to approximately 107 weeks
  18. Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)Time frame: Up to approximately 97 weeks
  19. Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)Time frame: Up to approximately 107 weeks
  20. Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)Time frame: Up to approximately 97 weeks
  21. Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)Time frame: Up to approximately 107 weeks
  22. Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)Time frame: Up to approximately 97 weeks
  23. Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)Time frame: Up to approximately 107 weeks
  24. Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)Time frame: Up to approximately 97 weeks
  25. Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)Time frame: Up to approximately 107 weeks
  26. Part 2: Overall Survival (OS)Time frame: Up to approximately 107 weeks

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational SIte

    Nashville, Tennessee

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Brampton, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Großhansdorf, Germany

  • GSK Investigational Site

    Meldola FC, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Siena, Italy

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Málaga, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.